XERIS PHARMACEUTICALS INC
NASDAQ: XERS (Xeris Biopharma Holdings, Inc.)
Kemas kini terakhir: 5 jam lalu7.45
-0.22 (-2.87%)
| Penutupan Terdahulu | 7.67 |
| Jumlah Dagangan | 1,598,308 |
| Harga / Pendapatan (P/E Ke hadapan) | 36.50 |
| Harga / Jualan (P/S) | 4.01 |
| Harga / Buku (P/B) | 107.68 |
| Julat 52 Minggu |
| Margin Keuntungan | -20.25% |
| Margin Operasi (TTM) | -5.14% |
| EPS Cair (TTM) | -0.290 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 47.90% |
| Nisbah Semasa (MRQ) | 1.72 |
| Aliran Tunai Operasi (OCF TTM) | -26.71 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.90 M |
| Pulangan Atas Aset (ROA TTM) | -3.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Xeris Biopharma Holdings, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.19% |
| % Dimiliki oleh Institusi | 54.46% |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HECHT BETH | - | 8.43 | -16,666 | -140,494 |
| MCCULLOCH KEVIN | - | 8.43 | -15,000 | -126,450 |
| PIEPER STEVEN | - | 8.43 | -5,000 | -42,150 |
| Jumlah Keseluruhan Kuantiti Bersih | -36,666 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -309,094 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 8.43 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PIEPER STEVEN | Pegawai | 01 Sep 2026 | Jual automatik (-) | 5,000 | 8.43 | 42,150 |
| HECHT BETH | Pegawai | 01 Sep 2026 | Jual automatik (-) | 16,666 | 8.43 | 140,494 |
| MCCULLOCH KEVIN | Pegawai | 01 Sep 2026 | Jual automatik (-) | 15,000 | 8.43 | 126,450 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |